INVO Bioscience (NASDAQ:INVO – Get Rating) and iRhythm Technologies (NASDAQ:IRTC – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.
Profitability
This table compares INVO Bioscience and iRhythm Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INVO Bioscience | -1,325.18% | -470.79% | -183.64% |
| iRhythm Technologies | -28.27% | -35.85% | -19.81% |
Analyst Recommendations
This is a summary of current recommendations and price targets for INVO Bioscience and iRhythm Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INVO Bioscience | 0 | 0 | 0 | 0 | N/A |
| iRhythm Technologies | 0 | 2 | 8 | 0 | 2.80 |
Earnings & Valuation
This table compares INVO Bioscience and iRhythm Technologies’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INVO Bioscience | $3.59 million | 1.38 | -$10.89 million | ($0.90) | -0.40 |
| iRhythm Technologies | $410.92 million | 9.86 | -$116.15 million | ($3.89) | -34.20 |
INVO Bioscience has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than INVO Bioscience, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
10.9% of INVO Bioscience shares are owned by institutional investors. Comparatively, 99.0% of iRhythm Technologies shares are owned by institutional investors. 10.4% of INVO Bioscience shares are owned by insiders. Comparatively, 1.6% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
INVO Bioscience has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Summary
iRhythm Technologies beats INVO Bioscience on 8 of the 13 factors compared between the two stocks.
About INVO Bioscience
IINVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.
About iRhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
